Nureca Limited has informed the Exchange regarding Re-Appointment of Aryan Goyal as Managing Director & CEO of the company for a period of Three years w.e.f. May 28, 2027.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited held a board meeting on May 29, 2026 and approved multiple items. Financially, the company reported Q4 FY26 standalone revenue of Rs. 354.05 million and full year revenue of Rs. 1,472.10 million, up 28.4% YoY. However, Q4 showed a loss of Rs. 61.52 million due to Rs. 83.37 million fair value loss on investments, while full year profit before tax was Rs. 28.36 million (vs loss of Rs. 4.60 million in FY25). The auditors gave an unmodified opinion. In leadership changes, CFO Mr. Naresh Gupta resigned effective June 26, 2026 citing better career opportunities, and was immediately replaced by Mr. Chander Kant (promoted from Manager Finance) effective June 27, 2026. The board also re-appointed Mr. Aryan Goyal as CEO and Mr. Saurabh Goyal as Managing Director for 3 years each, and appointed Ms. Smita Goyal as Additional Director (Whole Time Director). Additionally, the board approved Rs. 100 crore capex for medical device manufacturing and land purchase for expansion at Derabassi, Punjab.
Positive signals include revenue growth, internal CFO succession ensuring continuity, and capex investment for expansion. However, Q4 loss due to investment mark-to-market losses and ongoing family concentration in management (three Goyals on board) may raise governance concerns for some investors.